At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Resveratroldrug
Likely dose
Resveratrol 1,000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans
In Brief
A Phase 2 clinical trial evaluating Resveratrol for Type 2 Diabetes Mellitus and Insulin Resistance. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Resveratrol is a natural polyphenol (a compound containing a phenol functional group) that can be found in many plants. The purpose of this research is to study the effects of resveratrol on the action of insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in the blood), fat accumulation, and inflammation in the body.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus, Insulin Resistance
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMay 2011
Primary CompletionSep 2017
TodayJul 2026
First PostedMay 17, 2011
Enrollment StartMar 1, 2008
Primary CompletionSep 15, 2017
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 15.1 years ago
Interventions
Resveratroldrug
1,000mg twice daily for 28 days